The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.

OBJECTIVE To determine the incidence of depression, anxiety, and suicidality in patients with psoriasis compared with the general population. DESIGN A population-based cohort study using data collected as part of patient's electronic medical record from 1987 to 2002. SETTING General Practice Research Database. PATIENTS Analyses included 146 042 patients with mild psoriasis, 3956 patients with severe psoriasis, and 766 950 patients without psoriasis. Five controls without psoriasis were selected from the same practices and similar cohort entry dates as patients with psoriasis. MAIN OUTCOME MEASURE Clinical diagnoses of depression, anxiety, and suicidality among patients. RESULTS The adjusted hazard ratios (HRs) for receiving a diagnosis of depression, anxiety, and suicidality in patients with psoriasis compared with controls were 1.39 (95% confidence interval [CI], 1.37-1.41), 1.31 (95% CI, 1.29-1.34), and 1.44 (95% CI, 1.32-1.57), respectively. The adjusted HR of depression was higher in severe (HR, 1.72; 95% CI, 1.57-1.88) compared with mild psoriasis (HR, 1.38; 95% CI, 1.35-1.40). Younger patients with psoriasis had elevated HRs of outcomes compared with older patients with psoriasis. CONCLUSIONS Patients with psoriasis have an increased risk of depression, anxiety, and suicidality. We estimate that in the United Kingdom, in excess of 10 400 diagnoses of depression, 7100 diagnoses of anxiety, and 350 diagnoses of suicidality are attributable to psoriasis annually. It is important for clinicians to evaluate patients with psoriasis for these conditions to improve outcomes. Future investigation should determine the mechanisms by which psoriasis is associated with psychiatric outcomes as well as approaches for prevention.

[1]  C. Main,et al.  Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. , 2003, Archives of dermatology.

[2]  Andrea B Troxel,et al.  The risk of mortality in patients with psoriasis: results from a population-based study. , 2007, Archives of dermatology.

[3]  W. Bilker,et al.  The relationship between time since registration and measured incidence rates in the General Practice Research Database , 2005, Pharmacoepidemiology and drug safety.

[4]  Corri Black,et al.  Validity of the General Practice Research Database , 2003, Pharmacotherapy.

[5]  H. Jick,et al.  A study of the relation of exposure to quinolones and suicidal behaviour. , 1998, British Journal of Clinical Pharmacology.

[6]  R. Jenkins,et al.  Potential for suicide prevention in primary care? An analysis of factors associated with suicide. , 1998, The British journal of general practice : the journal of the Royal College of General Practitioners.

[7]  R. Schlienger,et al.  Current Use of Selective Serotonin Reuptake Inhibitors and Risk of Acute Myocardial Infarction , 2004, Drug safety.

[8]  R. Charlton,et al.  Data Resources for Investigating Drug Exposure during Pregnancy and Associated Outcomes , 2008, Drug safety.

[9]  M. Gupta,et al.  Depression Modulates Pruritus Perception: A Study of Pruritus in Psoriasis, Atopic Dermatitis and Chronic Idiopathic Urticaria a , 1999, Psychosomatic medicine.

[10]  Daniel B. Shin,et al.  The risk of lymphoma in patients with psoriasis. , 2006, The Journal of investigative dermatology.

[11]  R. Stern,et al.  Epidemiology of psoriatic arthritis in the population of the United States. , 2005, Journal of the American Academy of Dermatology.

[12]  S. Chimenti,et al.  An Italian Study on Psoriasis and Depression , 2006, Dermatology.

[13]  B. Bradbury,et al.  Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. , 2003, British journal of clinical pharmacology.

[14]  B. Gersh.  Risk of Myocardial Infarction in Patients With Psoriasis , 2007 .

[15]  H. Kumbasar,et al.  The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients , 1998, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  M. Zimmerman,et al.  Pathological worry in depressed and anxious patients. , 2003, Journal of anxiety disorders.

[17]  Susan S Jick,et al.  The Risk of Severe Depression, Psychosis or Panic Attacks with Prophylactic Antimalarials , 2004, Drug safety.

[18]  David J Margolis,et al.  Determinants of quality of life in patients with psoriasis: a study from the US population. , 2004, Journal of the American Academy of Dermatology.

[19]  J. Gelfand,et al.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. , 2009, Journal of the American Academy of Dermatology.

[20]  D. Margolis,et al.  Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. , 2005, Archives of dermatology.

[21]  B. Thiers.  Pathogenesis and clinical features of psoriasis , 2008 .

[22]  D. Mines,et al.  Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram , 2005, Pharmacoepidemiology and drug safety.

[23]  J. Gelfand,et al.  Update on the epidemiology and systemic treatment of psoriasis , 2007, Expert review of clinical immunology.

[24]  D. Ford,et al.  Role of Depression in Quality of Life for Patients with Psoriasis , 2007, Dermatology.

[25]  N. Schork,et al.  SUICIDAL IDEATION IN PSORIASIS , 1993, International journal of dermatology.

[26]  A. Gottlieb,et al.  Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial , 2006, The Lancet.